COVID-19: A Drug Repurposing and Biomarker Identification by Using Comprehensive Gene-Disease Associations through Protein-Protein Interaction Network Analysis

COVID-19 (2019-nCoV) is a pandemic disease with an estimated mortality rate of 3.4% (estimated by the WHO as of March 3, 2020). Until now there is no antiviral drug and vaccine for COVID-19. The current overwhelming situation by COVID-19 patients in hospitals is likely to increase in the next few months. About 15 percent of patients with serious disease in COVID-19 require immediate health services. Rather than waiting for new anti-viral drugs or vaccines that take a few months to years to develop and test, several researchers and public health agencies are attempting to repurpose medicines that are already approved for another similar disease and have proved to be fairly effective. This study aims to identify FDA approved drugs that can be used for drug repurposing and identify biomarkers among highrisk and asymptomatic groups. In this study gene-disease association related to COVID-19 reported mild, severe symptoms and clinical outcomes were determined. The high-risk group was studied related to SARS-CoV-2 viral entry and life cycle by using Disgenet and compared with curated COVID-19 gene data sets from the CTD database. The overlapped gene sets were enriched and the selected genes were constructed for protein-protein interaction networks. Through interactome, key genes were identified for COVID-19 and also for high risk and asymptomatic groups. The key hub genes involved in COVID-19 were VEGFA, TNF, IL-6, CXCL8, IL10, CCL2, IL1B, TLR4, ICAM1, MMP9. The identified key genes were used for drug-gene interaction for drug repurposing. The chloroquine, lenalidomide, pentoxifylline, thalidome, sorafenib, pacitaxel, rapamycin, cortisol, statins were proposed to be probable drug repurposing candidates for the treatment of COVID-19. However, these predicted drug candidates need to be validated through randomized clinical trials. Also, a key gene involved in high risk and the asymptomatic group were identified, which can be used as probable biomarkers for early identification.

[1]  J. Stein,et al.  A pilot trial of pentoxifylline on endothelial function and inflammation in HIV-infected patients initiating antiretroviral therapy. , 2016, AIDS.

[2]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2019 , 2018, Nucleic Acids Res..

[3]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Perlman,et al.  Another Decade, Another Coronavirus , 2020, The New England journal of medicine.

[5]  E. Shankar,et al.  Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins? , 2017, EBioMedicine.

[6]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[7]  D. Beezhold,et al.  ICAM-1 regulates the survival of influenza virus in lung epithelial cells during the early stages of infection. , 2016, Virology.

[8]  Chung-Yen Lin,et al.  cytoHubba: identifying hub objects and sub-networks from complex interactome , 2014, BMC Systems Biology.

[9]  Xinchun Chen,et al.  Genetic variants in IL1A and IL1B contribute to the susceptibility to 2009 pandemic H1N1 influenza A virus , 2013, BMC Immunology.

[10]  M. Meneghetti,et al.  Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity , 2018, International journal for parasitology. Drugs and drug resistance.

[11]  Hyun Kook Cho,et al.  Sorafenib suppresses hepatitis B virus gene expression via inhibiting JNK pathway , 2015 .

[12]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  gui-qiang Wang,et al.  A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option , 2020, Journal of medical virology.

[14]  L. Fantuzzi,et al.  The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy? , 2015, Current drug targets.

[15]  R. Tiwari,et al.  COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics , 2020, Human vaccines & immunotherapeutics.

[16]  Jörn Lötsch,et al.  Use of Computational Functional Genomics in Drug Discovery and Repurposing for Analgesic Indications , 2018, Clinical pharmacology and therapeutics.

[17]  Carolina L. Bellera,et al.  Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics , 2019, Expert opinion on drug discovery.

[18]  Fang Liu,et al.  Anti-HIV, antitumor and immunomodulatory activities of paclitaxel from fermentation broth using molecular imprinting technique , 2019, AMB Express.

[19]  Haibo Xu,et al.  Clinical course and outcome of novel coronavirus COVID-19 infection in 107 patients discharged from the Wuhan hospital , 2020 .

[20]  T. Sasazuki,et al.  Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry , 2008, Proceedings of the National Academy of Sciences.

[21]  Y. Hayashi,et al.  An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy , 2016, Journal of medicinal chemistry.

[22]  L. Teyton,et al.  Interleukin-10 determines viral clearance or persistence in vivo , 2006, Nature Medicine.

[23]  K. Kehn-Hall,et al.  Repurposed FDA‐Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses , 2018, Antiviral research.

[24]  Suresh Kumar.  Drug and Vaccine Design against Novel Coronavirus (2019-nCoV) Spike Protein through Computational Approach , 2020 .

[25]  Kwang Seok Kim,et al.  Induction of interleukin‐1 beta (IL‐1β) is a critical component of lung inflammation during influenza A (H1N1) virus infection , 2015, Journal of medical virology.

[26]  B. Torbett,et al.  mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3 , 2018, Proceedings of the National Academy of Sciences.

[27]  Jianguo Wu,et al.  Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2 , 2020, Journal of medical virology.

[28]  Michael G. Katze,et al.  Into the Eye of the Cytokine Storm , 2012, Microbiology and Molecular Reviews.

[29]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[30]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[31]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[32]  Michael Imbeault,et al.  The importance of virus‐associated host ICAM‐1 in human immunodeficiency virus type 1 dissemination depends on the cellular context , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  D. Meyer‐Olson,et al.  CCL2: A potential prognostic marker and target of anti‐inflammatory strategy in HIV/AIDS pathogenesis , 2011, European journal of immunology.

[34]  Jeong-Ki Kim,et al.  Lipophilic statins inhibit Zika virus production in Vero cells , 2019, Scientific Reports.

[35]  Weiliang Zhu,et al.  An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development. , 2006, Current pharmaceutical design.

[36]  A. Dabo,et al.  Matrix Metalloproteinase 9 Exerts Antiviral Activity against Respiratory Syncytial Virus , 2015, PloS one.

[37]  P. Woo,et al.  Identification of a Novel Coronavirus in Bats , 2005, Journal of Virology.

[38]  M. Chan-yeung,et al.  Short burst oxygen therapy for relief of breathlessness in COPD , 2004, Thorax.

[39]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[40]  F. Sanz,et al.  The DisGeNET knowledge platform for disease genomics: 2019 update , 2019, Nucleic Acids Res..

[41]  N. Mukaida.  Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[42]  Z. Tong,et al.  Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak , 2020, Journal of medical virology.

[43]  Atsushi Okumura,et al.  Interaction between Ebola Virus Glycoprotein and Host Toll-Like Receptor 4 Leads to Induction of Proinflammatory Cytokines and SOCS1 , 2009, Journal of Virology.

[44]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[45]  J. Parry,et al.  China coronavirus: cases surge as official admits human to human transmission , 2020, BMJ.

[46]  J. Tam,et al.  Human Coronaviruses: A Review of Virus–Host Interactions , 2016, Diseases.

[47]  E. Holmes,et al.  The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.

[48]  R. Zinkernagel,et al.  On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases , 1989, European journal of immunology.

[49]  G. Whittaker,et al.  Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein , 2012, Viruses.

[50]  Tao Zhang,et al.  Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak , 2020, Current Biology.

[51]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[52]  B. K. McIntosh,et al.  Representing virus-host interactions and other multi-organism processes in the Gene Ontology , 2015, BMC Microbiology.

[53]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.